Telix Faces Securities Class Action Over Prostate Cancer Disclosures and Supply Chain Claims

Overview

• The complaint, captioned Thomas v. Telix Pharmaceuticals Ltd., was filed in the U.S. District Court for the Southern District of Indiana covering purchases from Feb. 21, 2025 to Aug. 28, 2025.
• Plaintiffs allege Telix overstated the progress and commercial prospects of prostate cancer candidates TLX591 and TLX592.
• The suit also claims Telix misrepresented the stability, quality, and regulatory compliance of third‑party manufacturing and supply partners.
• On July 22, 2025, Telix disclosed an SEC subpoena seeking information about its prostate therapeutics disclosures, after which its ADSs fell more than 13% over two sessions, according to the complaint.
• On Aug. 28, 2025, Telix announced an FDA Complete Response Letter for TLX250‑CDx citing CMC deficiencies and Form 483s to two third‑party partners, and the complaint reports a further ADS decline of more than 21%.